A2Z to begin reagent production
Prague – A2Z Bio, the Czech subsidiary of UK-based Yorkshire Bioscience, is investing EUR100,000 at the CKD Prague Technological Innovation Centre to launch production of research reagents and services for the biotech R&D market. The company also announced it is hiring 5-6 experts plus administrative staff. Starting in September, A2Z Bio will begin manufacturing antibodies, oligonucleotides, synthetic genes and related services at the Prague site. “We will also offer the opportunity to outsource research to us,” explained
Slava Pavlovets, director of A2Z Bio.
“Biotechnology has a very promising future in the Czech Republic. The sector will be shaped primarily by smaller firms that nevertheless can offer leading technologies and unique know-how,” said Alexandra Rudyšarová, acting CEO of CzechInvest. According to the state promotional agency, about 10% of the countrys’ industry applications make use of biotechnologies.
A2Z Bio wants to sell products and services worth a250,000 in the first year of operations. “This is not just a one-off investment,” explained Pavlovets. “Our expansion to the Czech Republic is a long-term undertaking. We will invest much more in the Czech Republic.” A2Z Bio says it selected the Czech site because it offers an efficient connection to the whole of Europe.
“Our choices came down to southern Germany and the Czech Republic,” Pavlovets says. “In the end we decided for the Czech Republic because we will get much higher quality here for the same price.”